IL6 and neoplasm: Xenograft studies were repeated using the IL6R blocking antibody in vivo, and results demonstrate inhibition of IL6 signaling reduced tumorigenesis of SUM159 cells overexpressing CRYβB2, but had no significant effect on final tumor volume in CRYβB2P1-overexpressing cells (Fig. 7b, c).